MX2022015115A - Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos. - Google Patents

Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.

Info

Publication number
MX2022015115A
MX2022015115A MX2022015115A MX2022015115A MX2022015115A MX 2022015115 A MX2022015115 A MX 2022015115A MX 2022015115 A MX2022015115 A MX 2022015115A MX 2022015115 A MX2022015115 A MX 2022015115A MX 2022015115 A MX2022015115 A MX 2022015115A
Authority
MX
Mexico
Prior art keywords
methods
heart failure
activators
treating heart
cardiac sarcomere
Prior art date
Application number
MX2022015115A
Other languages
English (en)
Inventor
Narimon Honarpour
Malik Fady
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022015115A publication Critical patent/MX2022015115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan en el presente documento métodos para tratar a un sujeto con insuficiencia cardíaca, que comprende administrar al sujeto una dosis inicial de un activador de sarcómero cardíaco (CSA) durante un periodo de tiempo inicial, y administrar posteriormente al sujeto una dosis del CSA basada en la concentración en plasma del sujeto del CSA al final del periodo de tiempo inicial.
MX2022015115A 2017-06-30 2020-01-08 Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos. MX2022015115A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
MX2022015115A true MX2022015115A (es) 2023-01-18

Family

ID=63013097

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000190A MX2020000190A (es) 2017-06-30 2018-06-29 Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
MX2022015115A MX2022015115A (es) 2017-06-30 2020-01-08 Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020000190A MX2020000190A (es) 2017-06-30 2018-06-29 Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.

Country Status (10)

Country Link
US (3) US11576910B2 (es)
EP (1) EP3645002A1 (es)
JP (2) JP2020526483A (es)
CN (1) CN110996953A (es)
AU (2) AU2018290983B2 (es)
BR (1) BR112019028046A2 (es)
CA (1) CA3068588A1 (es)
MA (1) MA49508A (es)
MX (2) MX2020000190A (es)
WO (1) WO2019006235A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970123T3 (da) 2013-03-14 2019-10-21 Amgen Inc Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
AU2018290983B2 (en) * 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
PT3645518T (pt) 2017-06-30 2021-08-23 Amgen Inc Síntese de omecamtiv mecarbil
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
AU2021380754A1 (en) * 2020-11-12 2023-06-22 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
CN117157274A (zh) 2021-03-10 2023-12-01 安进股份有限公司 奥美卡替莫卡必尔的合成
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
ATE458534T1 (de) 2002-10-04 2010-03-15 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
JP5080970B2 (ja) 2004-06-17 2012-11-21 サイトキネティクス・インコーポレーテッド 心疾患を治療するための置換尿素誘導体
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
KR101034888B1 (ko) 2007-04-19 2011-05-17 동아제약주식회사 지속제어 방출 양상을 갖는 당조절 펩타이드 함유 생분해성고분자 미립구 및 그 제조방법
DK2970123T3 (da) 2013-03-14 2019-10-21 Amgen Inc Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
PT3645518T (pt) 2017-06-30 2021-08-23 Amgen Inc Síntese de omecamtiv mecarbil
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
ES2815899T3 (es) 2018-07-09 2021-03-31 Fis Fabbrica Italiana Sintetici Spa 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
US20220042055A1 (en) 2018-12-18 2022-02-10 Amgen Inc. Method of reducing aromatic nitro compounds
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070124A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
JP2023513249A (ja) 2020-02-10 2023-03-30 アムジェン インコーポレイテッド オメカムチブメカルビル製剤
AU2021380754A1 (en) 2020-11-12 2023-06-22 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
CN117157274A (zh) 2021-03-10 2023-12-01 安进股份有限公司 奥美卡替莫卡必尔的合成
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents

Also Published As

Publication number Publication date
CA3068588A1 (en) 2019-01-03
CN110996953A (zh) 2020-04-10
MA49508A (fr) 2020-05-06
US11576910B2 (en) 2023-02-14
MX2020000190A (es) 2020-07-22
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
US20230149394A1 (en) 2023-05-18
US11931358B2 (en) 2024-03-19
AU2018290983B2 (en) 2023-11-23
US20200155547A1 (en) 2020-05-21
EP3645002A1 (en) 2020-05-06
JP2020526483A (ja) 2020-08-31
AU2024200991A1 (en) 2024-03-07
US20230355615A1 (en) 2023-11-09
JP2023088944A (ja) 2023-06-27
WO2019006235A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
EP3346915A4 (en) Systems, devices, components and methods for detecting the locations of sources of cardiac rhythm disorders in a patient's heart
EP4252833A3 (en) Microstimulation sleep disordered breathing (sdb) therapy device
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
PH12017502103A1 (en) Methods and kits for treating depression
MX2018013354A (es) Terapia de combinacion para tratamiento de cancer.
MX2022008868A (es) Tratamiento del cancer con tg02.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
PH12020500555A1 (en) Esketamine for the treatment of depression
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2016000173A (es) Sistemas y metodos para seguimiento y presentacion de datos de terapia para acufenos.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
TW201613592A (en) Glucose metabolism ameliorating agent
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
MX2016009102A (es) Composiciones de enolasa 1 (eno1) y sus usos.
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
TW201613639A (en) Methods for treating cardiovascular diseases
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2015011930A (es) Activacion de adiponectina por hidrolizado de caseina.
MX2020008905A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.